Therapies in Development for the Treatment of Pancreatic Cancer

Margaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, discusses therapies that are currently in development for the treatment of pancreatic cancer.

Clinical Pearls

• Pathways that are downstream of activated RAS, such as the MAPK and PI3K pathways, are potential targets for the treatment of pancreatic cancer
• Stromal depleting agents are also in development
• There is a lot of interest in optimizing vaccine strategies and changing the immune cell population in the microenvironment from a pro-tumor environment to an anti-tumor environment